These observations suggest that neurexin-1 expression in tumours at diagnosis could be used for the early identification of patients with localised disease that relapse and may benefit from more intensive treatment or rapid transfer to early phase clinical trials of novel agents. This evidence concerns the gene NRXN1 and neoplasm.